Epidermal growth factor receptor L858R mutated allosteric inhibitor - Allorion Therapeutics/AstraZeneca
Alternative Names: EGFR L858R mutated allosteric inhibitor - Allorion TherapeuticsLatest Information Update: 01 Mar 2024
At a glance
- Originator Allorion Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 02 Jan 2024 Allorion Therapeutics enters into an exclusive option and global license agreement with AstraZeneca to develop and commercialize EGFR L858R mutated allosteric inhibitor for Non-small cell lung cancer
- 02 Jan 2024 Preclinical trials in Non-small cell lung cancer in China (unspecified route)
- 02 Jan 2024 Preclinical trials in Non-small cell lung cancer in USA (unspecified route)